Schizophrenia has heritability estimates of 70-85% 1 and genetic risk in most cases is presumably a result of multiple genetic loci of small effect. In recent years, genome-wide association studies have facilitated the discovery of potential risk genes for neuropsychiatric disorders. ZNF804A rs1344706 was the first single-nucleotide polymorphism (A/C, A ¼ risk allele) to show a significant association with schizophrenia in genome-wide association studies (P ¼ 1.6 Â 10
). 2 Although the physiological function of ZNF804A and its role in schizophrenia risk is currently unclear, the gene has been shown to be associated with psychosis, 3 and several potential intermediate biological phenotypes, such as deficits in executive function 4 and altered cortical connectivity during working memory 5, 6 and theory of mind. 7 Cognitive deficits in schizophrenia are broad and conspicuously include deficits in cognitive control, an executive function that refers to the ability to direct behavior toward a goal in the presence of conflict. Studies have shown altered function and connectivity of the dorsolateral prefrontal cortex (DLPFC) and anterior cingulate cortex (ACC) in patients with schizophrenia during cognitive control tasks. 8 Recently, these alterations have been suggested to represent an intermediate phenotype because they are also found in healthy siblings of patients with schizophrenia. 9, 10 In this study, we aimed to explore the role of ZNF804A rs1344706 on activation and functional connectivity measures related to cognitive control. To this end, we used the Modified Flanker task that includes response inhibition (RI) and interference monitoring and suppression (IMS), two important components of cognitive control function. A total of 208 Caucasian healthy volunteers with no history of psychosis and no first-degree relatives with a schizophrenia spectrum disorder and with good quality functional magnetic resonance imaging (fMRI) data and genotype information for ZNF804A rs1344706 were selected from the larger sample of the Clinical Brain Disorders Branch Sibling Study of schizophrenia at the National Institute of Mental Health (DR Weinberger PI). In all, 89 subjects were rs1344706 AA homozygotes, 93 were rs1344706 AC heterozygotes and 26 were rs1344706 CC homozygotes. The genotype groups did not differ across demographic and task performance variables based on ANOVA and chi-square analyses (see Supplementary Materials, Supplementary Table 1) .
Subjects underwent BOLD fMRI using a gradient echoplanar imaging sequence on a 3T GE Signa scanner during which they performed a modified Flanker Task. fMRI data was processed using SPM5 (SPM; http://www.fil.ion.ucl.ac.uk). Genotype effects on cognitive control-dependent neural response and connectivity were tested using random-effects general linear model ANOVA analysis (Po0.05; small volume corrected P fdr o0.05) (see Supplementary Materials). To examine the cognitive control-dependent modulation of functional coupling of ACC and DLPFC, a psychophysiological interaction (PPI) analysis was performed using both ACC and right DLPFC as seed regions. The choice of ACC (identified through WFU-pickatlas toolbox; http:// fmri.wfubmc.edu/software/PickAtlas) as one of the seed regions was based on an earlier observation of altered ACC/DLPFC coupling during cognitive control representing a potential intermediate phenotype. 9 The choice of the second seed region in the right DLPFC (right Brodmann areas 9 and 46) was based on results from previous studies, 5, 6 which showed that the coupling of this brain region with other brain regions is modulated by ZNF804A rs1344706 during cognitive processing (see Supplementary Materials).
During RI, although there was no significant difference in activation across genotype groups, PPI analysis revealed increased connectivity between the ACC and right DLPFC in A, risk allele, homozygotes as well as heterozygotes when compared with C homozygotes. This was observed irrespective of the seed region, the right DLPFC (x, y, z ¼ 6, 27, 21, Z ¼ 3.73, P fdr ¼ 0.037, see Figure 1a ) or ACC, although the latter did not survive correction for multiple comparisons (P ¼ 0.006 uncorrected). There were no other areas that showed a significant effect of genotype on functional coupling with the seed regions during RI. During IMS, A, risk allele, homozygotes as well as heterozygotes showed decreased right DLPFC and ACC activation when compared with C homozygotes (DLPFC: x, y, z ¼ 51, 39, 15, Z ¼ 4.00, P fdr ¼ 0.011; ACC: x, y, z ¼ 3, 30, 27, Z ¼ 2.79, P fdr ¼ 0.026; see Figure 1b ). PPI Letters to the Editor revealed no significant difference in connectivity across genotype groups during IMS.
Our results show that ZNF804A modulates mechanisms underlying cognitive control. The ZNF804A rs1344706 allele load effect on ACC-PFC coupling, with risk allele carriers showing increased coupling, adds to evidence that ZNF804A modulates cortical network connectivity during executive cognition. 5 We have previously found that this pattern of enhanced ACC-PFC functional coupling is associated with schizophrenia and with increased genetic risk for schizophrenia, 9 suggesting that it is an intermediate biological phenotype related to the genetic risk architecture of illness. This adds to evidence that ZNF804a may confer risk for schizophrenia by impacting this intermediate phenotype mechanism.
Interestingly, we also found that ZNF804A modulates ACC and DLPFC activation during IMS. Although a similar alteration in ACC and DLPFC activation during IMS was observed in patients with SCZ, 9 it has not been shown to be an intermediate phenotype related to risk for schizophrenia. Therefore, further studies may be necessary to clarify if this effect of ZNF804A on ACC and DLPFC activation during IMS is independent of the mechanism through which it confers genetic risk for schizophrenia. Previous studies show an association between depression and elevated acute phase proteins such as fibrinogen, 2,3 but results are conflicting. [4] [5] [6] Furthermore, the association between depression and inflammatory markers may be confounded by health behaviors, for example, smoking, physical activity and body mass index, as well as by chronic disease. [7] [8] [9] [10] We tested the hypothesis that elevated plasma fibrinogen levels are associated with psychological distress and depression after adjustment for possible confounders.
We included 73 367 men and women aged 20-100 years from two independent population-based studies, the Copenhagen General Population Study and the Copenhagen City Heart Study. At the day of attendance, participants gave information about their level of physical activity and smoking status, and body mass index was measured. Blood samples were drawn and fibrinogen measured using a calorimetric or a turbidimetry method (Boehringer Mannheim, Mannheim, Germany or Instrumentation Laboratory, Milano, Italy). Symptoms of psychological distress were ascertained as confirmative answers to one or more of the three questions ('Do you have the feeling that you have not accomplished very much recently?', 'Do you feel like giving up?', and 'Do you often feel nervous or stressed?'). Depression was ascertained in three different ways: First, self-reported use of antidepressant medication was ascertained as a confirmative answer to the question 'Do you daily (or most days) use antidepressants, sedatives or relaxing pills?'. Second, because antidepressant medication can only be obtained by prescription in Denmark, we collected information about all such prescriptions claimed by study participants for at least 6 continuous months from 1994 through 2009 from the Danish Register of Medicinal Product Statistics. Third, diagnoses of depression were obtained from the Danish Patient Registry, which has information on all hospital discharge diagnoses. Depression was classified according to the International Classification of Diseases Eight Edition (ICD8) codes 296.0, 296.2, 298.0 and 300.4 until 1994, and Tenth Edition (ICD10) codes F32 and F33 from 1994 through 2010. Diagnoses of chronic disease were obtained from the Danish Patient Registry and included ischemic heart disease, myocardial infarction, stroke, diabetes, hypertension, cancer, pneumonia, chronic obstructive pulmonary disease, asthma, deep venous thrombosis and pulmonary embolism.
We tested the association between elevated fibrinogen and psychological distress and depression cross-sectionally in the entire study population. We used multivariable adjusted logistic regression models to calculate odds ratios with 95% confidence intervals in two different models. In the first model, we adjusted for age, gender, smoking, physical activity and body mass index. In the second model, we adjusted for age, gender, smoking, physical activity, body mass index and chronic disease.
In the first model, an increase in fibrinogen quartiles was associated with an increased risk of not accomplishing, of giving up, of self-reported antidepressant medication, of prescription antidepressant medication, and of hospitalization with depression (P-trend: 0.01 to 9*10 À 22 ) ( Figure 1 ). There was no association between an increase in fibrinogen quartiles and feeling nervous or stressed (P-trend ¼ 0.38). There was a 25-50% increased risk for psychological distress for participants in the highest fibrinogen quartile versus the lowest quartile in the first model. Similarly, there was a 20-90% increased risk of depression, highest for the endpoints prescription antidepressant medication and hospitalization with depression. Adding chronic disease to the first model only slightly attenuated risk estimates.
An important strength of our study is the large number of participants and well-determined confounders. From the Danish Patient Registry and Danish Register of Medical Product Statistics, we had 100% complete data on all participants on hospitalization with depression, chronic diseases and prescription antidepressant medication. Furthermore, we observed an association between fibrinogen levels and each of the different endpoints, except for the endpoint of feeling nervous or stressed, emotions not generally included among depressive symptoms. This negative finding adds credibility to the positive findings for psychological distress and depression. A weakness of this paper is the absence of longitudinal data, and we therefore cannot be sure that increased fibrinogen levels are not a consequence of depression. Another weakness is that a diagnostic scoring scale of depression was not used in this population.
In conclusion, elevated plasma fibrinogen levels were associated with psychological distress and depression in 73 367 individuals from the general population after adjusting for confounders.
